Recent advances in protein and peptide drug delivery: A special emphasis on polymeric nanoparticles

Protein and Peptide Letters

Volumn 21, Issue 11, 2014, Pages 1102-1120

  Patel, Ashaben ^a   Patel, Mitesh ^a   Yang, Xiaoyan ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Brain; Hydrophobic ion pairing (HIP) complex; Nasal; Ocular; Parenteral; Polymeric nanoparticles; Protein and peptide drug delivery; Pulmonary; Transdermal

Indexed keywords

AFLIBERCEPT; ASPARAGINASE; BELATACEPT; BELIMUMAB; BOTULINUM TOXIN A; BRENTUXIMAB VEDOTIN; CLOSTRIDIOPEPTIDASE A; DENOSUMAB; INSULIN; INSULIN ASPART; IPILIMUMAB; LEUPRORELIN; OCRIPLASMIN; PEGLOTICASE; PEPTIDE; PROTEIN; RAXIBACUMAB; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; SALCATONIN; TESAMORELIN; TOCILIZUMAB; VELAGLUCERASE ALFA; NANOPARTICLE; POLYMER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTHRAX; ARTICLE; BRAIN CAPILLARY ENDOTHELIAL CELL; CERVICAL DYSTONIA; COLORECTAL CANCER; DENATURATION; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG SOLUBILITY; DUPUYTREN CONTRACTURE; EMULSION SOLVENT EVAPORATION METHOD; ENCAPSULATION; ENZYME DEGRADATION; FREEZE DRYING; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; GOUT; GRAFT REJECTION; HODGKIN DISEASE; HUMAN; HYDROPHOBICITY; INTESTINE CELL; IONIC GELATION AND COCERVATION TECHNIQUE; JUVENILE RHEUMATOID ARTHRITIS; LARGE CELL LYMPHOMA; LIPODYSTROPHY; MEDICAL LITERATURE; MELANOMA; METHODOLOGY; NANOPRECIPITATION METHOD; NANOTECHNOLOGY; NONHUMAN; PEYER PATCH; POSTMENOPAUSE OSTEOPOROSIS; RHEUMATOID ARTHRITIS; SUPERCRITICAL FLUID; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCYTOSIS; ANIMAL; CHEMISTRY; MOUSE;

ANIMALS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; MICE; NANOPARTICLES; PEPTIDES; POLYMERS; PROTEINS;

EID: 84908436877     PISSN: 09298665     EISSN: 18755305     Source Type: Journal    
DOI: 10.2174/0929866521666140807114240     Document Type: Article

References (173)

1. Tan, M. L.; Choong, P. F.; Dass, C. R. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides, 2010, 31(1), 184-93.
2. Patel, A.; Cholkar, K.; Mitra, A. K. Recent Developments in Protein and Peptide Parenteral Delivery Approaches. Ther. Delivery, 2014, 5(3), 337-65.
3. Kumar, T. R.; Soppimath, K.; Nachaegari, S. K. Novel delivery technologies for protein and peptide therapeutics. Curr. Pharm. Biotechnol., 2006, 7(4), 261-76.
4. Jitendra.; Sharma, P. K.; Bansal, S.; Banik, A. Noninvasive routes of proteins and peptides drug delivery. Indian J. Pharm. Sci., 2011, 73(4), 367-75.
5. Lee, C.; Choi, J. S.; Kim, I.; Oh, K. T.; Lee, E. S.; Park, E. S.; Lee, K. C.; Youn, Y. S. Long-acting inhalable chitosan-coated poly (lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes. Int. J. Nanomedicine, 2013, 8, 2975-83.
6. Pinto Reis, C.; Neufeld, R. J.; Ribeiro, A. J.; Veiga, F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine, 2006, 2(2), 53-65.
7. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y. J.; Préat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release, 2006, 116(1), 1-27.
8. Shukla, R. S.; Chen, Z.; Cheng, K. Strategies of drug targeting. In: Advanced Drug Delivery. 2013, Wiley. p. 105.
9. labels.fda.gov.
10. Vrignaud, S.; Benoit, J. P.; Saulnier, P. Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles. Biomaterials, 2011, 32(33), 8593-604.
11. Patel, A.; Cholkar, K.; Vibhuti, A.; Mitra, A. K. Ocular drug delivery systems: An overview. World J. Pharmacol., 2013, 2(2), 47-64.
12. Sung, H. W.; Sonaje, K.; Liao, Z. X.; Hsu, L. W.; Chuang, E. Y. pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications. Acc Chem. Res., 2012, 45(4), 619-29.
13. Iqbal, J.; Vigl, C.; Moser, G.; Gasteiger, M.; Perera, G.; Bernkop-Schnürch, A. Development and in vivo evaluation of a new oral nanoparticulate dosage form for leuprolide based on polyacrylic acid. Drug Deliv., 2011, 18(6), 432-40.
14. Mahapatro, A.; Singh, D. K. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J. Nanobiotechnol., 2011, 9, 55.
15. Cuña, M.; Alonso-Sandel, M.; Remuñán-López, C.; Pivel, J. P.; Alonso-Lebrero, J. L.; Alonso, M. J. Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery. J. Nanosci. Nanotechnol., 2006, 6(9-10), 2887-95.
16. Makhlof, A.; Werle, M.; Tozuka, Y.; Takeuchi, H. Nanoparticles of glycol chitosan and its thiolated derivative significantly improved the pulmonary delivery of calcitonin. Int. J. Pharm., 2010, 397(1-2), 92-5.
17. Sinsuebpol, C.; Chatchawalsaisin, J.; Kulvanich, P. Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery. Drug Des. Devel. Ther., 2013, 7, 861-73.
18. Yadav, S. C.; Kumari, A.; Yadav, R. Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation. Peptides, 2011, 32(1), 173-87.
19. Kafka, A. P.; McLeod, B. J.; Rades, T.; McDowell, A. Release and bioactivity of PACA nanoparticles containing D-Lys (6)-GnRH for brushtail possum fertility control. J. Control. Release, 2011, 149(3), 307-13.
20. Zhang, Q.; Shen, Z.; Nagai, T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int. J. Pharm., 2001, 218(1-2), 75-80.
21. Mukherjee, B.; Santra, K.; Pattnaik, G.; Ghosh, S. Preparation, characterization and in-vitro evaluation of sustained release proteinloaded nanoparticles based on biodegradable polymers. Int. J. Nanomedicine, 2008, 3(4), 487-96.
22. Eley, J. G.; Mathew, P. Preparation and release characteristics of insulin and insulin-like growth factor-one from polymer nanoparticles. J. Microencapsul., 2007, 24(3), 225-34.
23. Manuel, J.; Santander-Ortega, Csaba, N.; González, L.; Bastos-González, D.; Ortega-Vinuesa, J. L.; Maria, J. Alonso Proteinloaded PLGA-PEO blend nanoparticles: encapsulation, release and degradation characteristics. Colloid Polym. Sci., 2010, 288(2), 141-150.
24. Bilati, U.; Allemann, E.; Doelker, E. Nanoprecipitation versus emulsion-based techniques for the encapsulation of proteins into biodegradable nanoparticles and process-related stability issues. AAPS PharmSci. Tech., 2005, 6(4), E594-604.
25. van de Weert, M.; Hoechstetter, J.; Hennink, W. E.; Crommelin, D. J. The effect of a water/organic solvent interface on the structural stability of lysozyme. J. Control. Release, 2000, 68(3), 351-9.
26. Cleland, J. L.; Powell, M. F.; Shire, S. J. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst., 1993, 10(4), 307-77.
27. Varshochian, R.; Jeddi-Tehrani, M.; Mahmoudi, A. R.; Khoshayand, M. R.; Atyabi, F.; Sabzevari, A.; Esfahani, M. R.; Dinarvand, R. The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur. J. Pharm. Sci., 2013, 50(3-4), 341-52.
28. Stanwick, J. C.; Baumann, M. D.; Shoichet, M. S. Enhanced neurotrophin-3 bioactivity and release from a nanoparticle-loaded composite hydrogel. J. Control. Release, 2012, 160(3), 666-75.
29. Son, S.; Lee, W. R.; Joung, Y. K.; Kwon, M. H.; Kim, Y. S.; Park, K. D. Optimized stability retention of a monoclonal antibody in the PLGA nanoparticles. Int. J. Pharm., 2009, 368(1-2), 178-85.
30. Gaudana, R.; Khurana, V.; Parenky, A.; Mitra, A. K. Encapsulation of Protein-Polysaccharide HIP Complex in Polymeric Nanoparticles. J. Drug Deliv., 2011, 2011, 458128.
31. Patel, A.; Gaudana, R.; Mitra, A. K. A novel approach to antibody nanocarriers development through hydrophobic ionpairing complexation. J. Microencapsul., 2014, 31(6), 542-50.
32. Rastogi, R.; Anand, S.; Koul, V. Evaluation of pharmacological efficacy of 'insulin-surfoplex' encapsulated polymer vesicles. Int. J. Pharm., 2009, 373(1-2), 107-15.
33. Bilati, U.; Allemann, E.; Doelker, E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur. J. Pharm. Sci., 2005, 24(1), 67-75.
34. Gaudana, R.; Gokulgandhi, M.; Khurana, V.; Kwatra, D.; Mitra, A. K. Design and evaluation of a novel nanoparticulate-based formulation encapsulating a HIP complex of lysozyme. Pharm. Dev. Technol., 2013, 18(3), 752-9.
35. Vandana, M.; Sahoo, S. K. Optimization of physicochemical parameters influencing the fabrication of protein-loaded chitosan nanoparticles. Nanomedicine (Lond.), 2009, 4(7), 773-85.
36. Xu, Y.; Du, Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int. J. Pharm., 2003, 250(1), 215-26.
37. Elvassore, N.; Bertucco, A.; Caliceti, P. Production of insulinloaded poly (ethylene glycol)/poly (l-lactide) (PEG/PLA) nanoparticles by gas antisolvent techniques. J. Pharm. Sci., 2001, 90(10), 1628-36.
38. Marin, E.; Briceno, M. I.; Caballero-George, C. Critical evaluation of biodegradable polymers used in nanodrugs. Int. J. Nanomedicine, 2013, 8, 3071-90.
39. Goldberg, M.; Gomez-Orellana, I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov., 2003, 2(4), 289-95.
40. Salama, N. N.; Eddington, N. D.; Fasano, A. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev., 2006, 58(1), 15-28.
41. Lemmer, H. J.; Hamman, J. H. Paracellular drug absorption enhancement through tight junction modulation. Expert Opin. Drug Deliv., 2013, 10(1), 103-14.
42. Antunes, F.; Andrade, F.; Ferreira, D.; Nielsen, H. M.; Sarmento, B. Models to predict intestinal absorption of therapeutic peptides and proteins. Curr. Drug Metab., 2013, 14(1), 4-20.
43. Hamman, J. H.; Enslin, G. M.; Kotze, A. F. Oral delivery of peptide drugs: barriers and developments. BioDrugs, 2005, 19(3), 165-77.
44. Herrero, E. P.; Alonso, M. J.; Csaba, N. Polymer-based oral peptide nanomedicines. Ther. Deliv., 2012, 3(5), 657-68.
45. Witt, K. A.; Huber, J. D.; Egleton, R. D.; Roberts, M. J.; Bentley, M. D.; Guo, L.; Wei, H.; Yamamura, H. I.; Davis, T. P. Pharmacodynamic and pharmacokinetic characterization of poly (ethylene glycol) conjugation to met-enkephalin analog [D-Pen2, D-Pen5]-enkephalin (DPDPE). J. Pharmacol. Exp. Ther., 2001, 298(2), 848-56.
46. Xu, X.; Li, R.; Ma, M.; Wang, X.; Wang, Y.; Zou, H. Multidrug resistance protein P-glycoprotein does not recognize nanoparticle C60: experiment and modeling. Soft Matter, 2012, 8(10), 2915-2923.
47. Gupta, S.; Jain, A.; Chakraborty, M.; Sahni, J. K.; Ali, J.; Dang, S. Oral delivery of therapeutic proteins and peptides: a review on recent developments. Drug Deliv., 2013, 20(6), 237-46.
48. Brogden, R. N.; Heel, R. C. Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. Drugs, 1987, 34(3), 350-71.
49. Malik, D. K.; Baboota, S.; Ahuja, A.; Hasan, S.; Ali, J. Recent advances in protein and peptide drug delivery systems. Curr. Drug Deliv., 2007, 4(2), 141-51.
50. Shakweh, M.; Ponchel, G.; Fattal, E. Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin. Drug Deliv., 2004, 1(1), 141-63.
51. Desai, M. P.; Labhasetwar, V.; Amidon, G. L.; Levy, R. J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res., 1996, 13(12), 1838-45.
52. Coppi, G.; Sala, N.; Bondi, M.; Sergi, S.; Iannuccelli, V. Ex-vivo evaluation of alginate microparticles for Polymyxin B oral administration. J. Drug Target., 2006, 14(9), 599-606.
53. Giannasca, P. J.; Giannasca, K. T.; Leichtner, A. M.; Neutra, M. R. Human intestinal M cells display the sialyl Lewis A antigen. Infect. Immun., 1999, 67(2), 946-53.
54. Prego, C.; García, M.; Torres, D.; Alonso, M. J. Transmucosal macromolecular drug delivery. J. Control. Release, 2005, 101(1-3), 151-62.
55. Liu, Y.; Kong, M.; Feng, C.; Yang, K. K.; Li, Y.; Su, J.; Cheng, X. J.; Park, H. J.; Chen, X. G. Biocompatibility, cellular uptake and biodistribution of the polymeric amphiphilic nanoparticles as oral drug carriers. Colloids Surf. B Biointerfaces, 2013, 103, 345-53.
56. Delie, F.; Blanco-Prieto, M. J. Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules, 2005, 10(1), 65-80.
57. des Rieux, A.; Fievez, V.; Théate, I.; Mast, J.; Préat, V.; Schneider, Y. J. An improved in vitro model of human intestinal follicleassociated epithelium to study nanoparticle transport by M cells. Eur J. Pharm. Sci., 2007, 30(5), 380-91.
58. des Rieux, A.; Ragnarsson, E. G.; Gullberg, E.; Préat, V.; Schneider, Y. J.; Artursson, P. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur J. Pharm. Sci., 2005, 25(4-5), 455-65.
59. Jani, P.; Halbert, G. W.; Langridge, J.; Florence, A. T. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol., 1989, 41(12), 809-12.
60. Shakweh, M.; Besnard, M.; Nicolas, V.; Fattal, E. Poly (lactide-coglycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur. J. Pharm. Biopharm., 2005, 61(1-2), 1-13.
61. Tang, B. C.; Dawson, M.; Lai, S. K.; Wang, Y. Y.; Suk, J. S.; Yang, M.; Zeitlin, P.; Boyle, M. P.; Fu, J.; Hanes, J. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc. Natl. Acad. Sci. USA, 2009, 106(46), 19268-73.
62. Florence, A. T. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm. Res., 1997, 14(3), 259-66.
63. Florence, A. T.; Hillery, A. M.; Hussain, N.; Jani, P. U. Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J. Drug Target., 1995, 3(1), 65-70.
64. Reis, C. P.; Veiga, F. J.; Ribeiro, A. J.; Neufeld, R. J.; Damgé, C. Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response. J. Pharm. Sci., 2008, 97(12), 5290-305.
65. Cui, F.; Qian, F.; Zhao, Z.; Yin, L.; Tang, C.; Yin, C. Preparation, characterization, and oral delivery of insulin loaded carboxylated chitosan grafted poly (methyl methacrylate) nanoparticles. Biomacromolecules, 2009, 10(5), 1253-8.
66. Gupta, P. N.; Khatri, K.; Goyal, A. K.; Mishra, N.; Vyas, S. P. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J. Drug Target., 2007, 15(10), 701-13.
67. Yoo, M. K.; Kang, S. K.; Choi, J. H.; Park, I. K.; Na, H. S.; Lee, H. C.; Kim, E. B.; Lee, N. K.; Nah, J. W.; Choi, Y. J.; Cho, C. S. Targeted delivery of chitosan nanoparticles to Peyer's patch using M cellhoming peptide selected by phage display technique. Biomaterials, 2010, 31(30), 7738-47.
68. Jin, Y.; Song, Y.; Zhu, X.; Zhou, D.; Chen, C.; Zhang, Z.; Huang, Y. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials, 2012, 33(5), 1573-82.
69. Zhang, N.; Ping, Q.; Huang, G.; Xu, W.; Cheng, Y.; Han, X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm., 2006, 327(1-2), 153-9.
70. Lochner, N.; Pittner, F.; Wirth, M.; Gabor, F. Wheat germ agglutinin binds to the epidermal growth factor receptor of artificial Caco-2 membranes as detected by silver nanoparticle enhanced fluorescence. Pharm. Res., 2003, 20(5), 833-9.
71. Lee, G. Y.; Kim, J. H.; Oh, G. T.; Lee, B. H.; Kwon, I. C.; Kim, I. S. Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand. J. Control. Release, 2011, 155(2), 211-7.
72. Akala, E. O.; Elekwachi, O.; Chase V, Johnson H, Lazarre M, Scott K. Organic redox-initiated polymerization process for the fabrication of hydrogels for colon-specific drug delivery. Drug Dev. Ind. Pharm., 2003, 29(4), 375-86.
73. Chourasia, M. K.; Jain, S. K. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci., 2003, 6(1), 33-66.
74. Kompella, U. B.; Lee, V. H. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv. Drug Deliv. Rev., 2001, 46(1-3), 211-45.
75. Renukuntla, J.; Vadlapudi, A. D.; Patel, A.; Boddu, S. H.; Mitra, A. K. Approaches for enhancing oral bioavailability of peptides and proteins. Int. J. Pharm., 2013, 447(1-2), 75-93.
76. Sinha, V.; Singh, A.; Kumar, R. V.; Singh, S.; Kumria, R.; Bhinge, J. Oral colon-specific drug delivery of protein and peptide drugs. Crit. Rev. Ther. Drug Carrier Syst., 2007, 24(1), 63-92.
77. Haupt, S.; Rubinstein, A. The colon as a possible target for orally administered peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst., 2002, 19(6), 499-551.
78. Coco, R.; Plapied, L.; Pourcelle, V.; Jérôme, C.; Brayden, D. J.; Schneider, Y. J.; Préat, V. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int. J. Pharm., 2013, 440(1), 3-12.
79. Laroui, H.; Dalmasso, G.; Nguyen, H. T.; Yan, Y.; Sitaraman, S. V.; Merlin, D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology, 2010, 138(3), 843-53 e1-2.
80. Sharma, G.; van der Walle, C. F.; Ravi Kumar, M. N. Antacid coencapsulated polyester nanoparticles for peroral delivery of insulin: development, pharmacokinetics, biodistribution and pharmacodynamics. Int. J. Pharm., 2013, 440(1), 99-110.
81. Zhang, X.; Sun, M.; Zheng, A.; Cao, D.; Bi, Y.; Sun, J. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur. J. Pharm. Sci., 2012, 45(5), 632-8.
82. Cetin, M.; Aktas, M. S.; Vural, I.; Ozturk, M. Salmon calcitoninloaded Eudragit (R) and Eudragit (R)-PLGA nanoparticles: in vitro and in vivo evaluation. J. Microencapsul., 2012, 29(2), 156-66.
83. Xiong, X. Y.; Li, Y. P.; Li, Z. L.; Zhou, C. L.; Tam, K. C.; Liu, Z. Y.; Xie, G. X. Vesicles from Pluronic/poly (lactic acid) block copolymers as new carriers for oral insulin delivery. J. Control. Release, 2007, 120(1-2), 11-7.
84. Damgé, C.; Socha, M.; Ubrich, N.; Maincent, P. Poly (epsiloncaprolactone)/eudragit nanoparticles for oral delivery of aspartinsulin in the treatment of diabetes. J. Pharm. Sci., 2010, 99(2), 879-89.
85. Thompson, C. J.; Tetley, L.; Uchegbu, I. F.; Cheng, W. P. The complexation between novel comb shaped amphiphilic polyallylamine and insulin: towards oral insulin delivery. Int. J. Pharm., 2009, 376(1-2), 46-55.
86. Deutel, B.; Greindl, M.; Thaurer, M.; Bernkop-Schnürch, A. Novel insulin thiomer nanoparticles: in vivo evaluation of an oral drug delivery system. Biomacromolecules, 2008, 9(1), 278-85.
87. Prego, C.; Torres, D.; Alonso, M. J. Chitosan nanocapsules as carriers for oral peptide delivery: effect of chitosan molecular weight and type of salt on the in vitro behaviour and in vivo effectiveness. J. Nanosci. Nanotechnol., 2006, 6(9-10), 2921-8.
88. Sonaje, K.; Chen, Y. J.; Chen, H. L.; Wey, S. P.; Juang, J. H.; Nguyen, H. N.; Hsu, C. W.; Lin, K. J.; Sung, H. W. Enteric-coated capsules filled with freeze-dried chitosan/poly (gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials, 2010, 31(12), 3384-94.
89. Sonaje, K.; Lin, K. J.; Wey, S. P.; Lin, C. K.; Yeh, T. H.; Nguyen, H. N.; Hsu, C. W.; Yen, T. C.; Juang, J. H.; Sung, H. W. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials, 2010, 31(26), 6849-58.
90. Makhlof, A.; Tozuka, Y.; Takeuchi, H. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur. J. Pharm. Sci., 2011, 42(5), 445-51.
91. Su, F. Y.; Lin, K. J.; Sonaje, K.; Wey, S. P.; Yen, T. C.; Ho, Y. C.; Panda, N.; Chuang, E. Y.; Maiti, B.; Sung, H. W. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials, 2012, 33(9), 2801-11.
92. Yin, L.; Ding, J.; He, C.; Cui, L.; Tang, C.; Yin, C. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials, 2009, 30(29), 5691-700.
93. Rekha, M. R.; Sharma, C. P. Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. J. Control. Release, 2009, 135(2), 144-51.
94. Woitiski, C. B.; Neufeld, R. J.; Veiga, F.; Carvalho, R. A.; Figueiredo, I. V. Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur. J. Pharm. Sci., 2010, 41(3-4), 556-63.
95. Ribeiro, C.; Neto, A. P.; das Neves, J.; Bahia, M. F.; Sarmento, B. Preparation of polyelectrolyte nanocomplexes containing recombinant human hepatocyte growth factor as potential oral carriers for liver regeneration. Methods Mol. Biol., 2012, 811, 113-25.
96. Xiong, Y.; Qi, J.; Yao, P. Amphiphilic cholic-acid-modified dextran sulfate and its application for the controlled delivery of superoxide dismutase. Macromol. Biosci., 2012, 12(4), 515-24.
97. Woitiski, C. B.; Sarmento, B.; Carvalho, R. A.; Neufeld, R. J.; Veiga, F. Facilitated nanoscale delivery of insulin across intestinal membrane models. Int. J. Pharm., 2011, 412(1-2), 123-31.
98. Sarmento, B.; Ribeiro, A. J.; Veiga, F.; Ferreira, D. C.; Neufeld, R. J. Insulin-loaded nanoparticles are prepared by alginate ionotropic pre-gelation followed by chitosan polyelectrolyte complexation. J. Nanosci. Nanotechnol., 2007, 7(8), 2833-41.
99. Zhang, Y.; Wu, X.; Meng, L.; Zhang, Y.; Ai, R.; Qi, N.; He, H.; Xu, H.; Tang, X. Thiolated Eudragit nanoparticles for oral insulin delivery: preparation, characterization and in vivo evaluation. Int. J. Pharm., 2012, 436(1-2), 341-50.
100. Sakuma, S.; Suzuki, N.; Sudo, R.; Hiwatari, K.; Kishida, A.; Akashi, M. Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int. J. Pharm., 2002, 239(1-2), 185-95.
101. Turker, S.; Onur, E.; Ozer, Y. Nasal route and drug delivery systems. Pharm. World Sci., 2004, 26(3), 137-42.
102. Saindane, N. S.; Pagar, K. P.; Vavia, P. R. Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization. AAPS PharmSciTech, 2013, 14(1), 89-99.
103. Smart, J. D. Nasal and buccal drug delivery: management forum conference. Ther. Deliv., 2012, 3(7), 819-22.
104. Rapoport, A.; Winner, P. Nasal delivery of antimigraine drugs: clinical rationale and evidence base. Headache, 2006, 46(Suppl 4), S192-201.
105. Ugwoke, M. I.; Verbeke, N.; Kinget, R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol., 2001, 53(1), 3-21.
106. Arora, P.; Sharma, S.; Garg, S. Permeability issues in nasal drug delivery. Drug Discov. Today, 2002, 7(18), 967-75.
107. Merkus, F. W.; Verhoef, J. C.; Schipper, N. G.; Marttin, E. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv. Drug Deliv. Rev., 1998, 29(1-2), 13-38.
108. Huang, Y.; Donovan, M. D. Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption. Adv. Drug Deliv. Rev., 1998, 29(1-2), 147-155.
109. Paturi Durga, et al., Nasal and Pulmonary Delivery of Macromolecules to Treat Respiratory and Nonrespiratory Diseases, In: Pulmonary Nanomedicine, Pan Stanford Publishing, 2012, p. 45-102.
110. Wang, X.; Zheng, C.; Wu, Z.; Teng, D.; Zhang, X.; Wang, Z.; Li, C. Chitosan-NAC nanoparticles as a vehicle for nasal absorption enhancement of insulin. J. Biomed. Mater. Res. B Appl. Biomater., 2009, 88(1), 150-61.
111. Teijeiro-Osorio, D.; Remunan-Lopez, C.; Alonso, M. J. New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules. Biomacromolecules, 2009, 10(2), 243-9.
112. Goycoolea, F. M.; Lollo, G.; Remuñán-López, C.; Quaglia, F.; Alonso, M. J. Chitosan-alginate blended nanoparticles as carriers for the transmucosal delivery of macromolecules. Biomacromolecules, 2009, 10(7), 1736-43.
113. Jintapattanakit, A.; Peungvicha, P.; Sailasuta, A.; Kissel, T.; Junyaprasert, V. B. Nasal absorption and local tissue reaction of insulin nanocomplexes of trimethyl chitosan derivatives in rats. J. Pharm. Pharmacol., 2010, 62(5), 583-91.
114. Alam, M. I.; Beg, S.; Samad, A.; Baboota, S.; Kohli, K.; Ali, J.; Ahuja, A.; Akbar, M. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci., 2010, 40(5), 385-403.
115. Patel, M.; Vadlapatla, R. K.; Pal, D.; Mitra, A. K. Molecular and functional characterization of riboflavin specific transport system in rat brain capillary endothelial cells. Brain Res., 2012, 1468, 1-10.
116. Wen, M. M. Olfactory targeting through intranasal delivery of biopharmaceutical drugs to the brain: current development. Discov. Med., 2011, 11(61), 497-503.
117. Pardeshi, C. V.; Belgamwar, V. S. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin. Drug Deliv., 2013, 10(7), 957-72.
118. Bahadur, S.; Pathak, K. Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opin. Drug Deliv., 2012, 9(1), 19-31.
119. Mistry, A.; Stolnik, S.; Illum, L. Nanoparticles for direct nose-tobrain delivery of drugs. Int. J. Pharm., 2009, 379(1), 146-57.
120. Illum, L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci., 2000, 11(1), 1-18.
121. Thorne, R. G.; Frey, W. H.2nd. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet., 2001, 40(12), 907-46.
122. Chen, X. Q.; Fawcett, J. R.; Rahman, Y. E.; Ala, T. A.; Frey, II W. H. Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway. J. Alzheimers Dis., 1998, 1(1), 35-44.
123. Thorne, R. G.; Pronk, G. J.; Padmanabhan, V.; Frey, W. H.2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience, 2004, 127(2), 481-96.
124. Shi, C. G.; Wang, L. M.; Wu, Y.; Wang, P.; Gan, Z. J.; Lin, K.; Jiang, L. X.; Xu, Z. Q.; Fan, M. Intranasal administration of nerve growth factor produces antidepressant-like effects in animals. Neurochem. Res., 2010, 35(9), 1302-14.
125. Cheng, Q.; Feng, J.; Chen, J.; Zhu, X.; Li, F. Brain transport of neurotoxin-I with PLA nanoparticles through intranasal administration in rats: a microdialysis study. Biopharm. Drug Dispos., 2008, 29(8), 431-9.
126. Xia, H.; Gao, X.; Gu, G.; Liu, Z.; Zeng, N.; Hu, Q.; Song, Q.; Yao, L.; Pang, Z.; Jiang, X.; Chen, J.; Chen, H. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials, 2011, 32(36), 9888-98.
127. Veronesi, M. C.; Aldouby, Y.; Domb, A. J.; Kubek, M. J. Thyrotropin-releasing hormone d, l polylactide nanoparticles (TRH-NPs) protect against glutamate toxicity in vitro and kindling development in vivo. Brain Res., 2009, 1303, 151-60.
128. Ruan, Y.; Yao, L.; Zhang, B.; Zhang, S.; Guo, J. Antinociceptive properties of nasal delivery of neurotoxin-loaded nanoparticles coated with polysorbate-80. Peptides, 2011, 32(7), 1526-9.
129. Ruan, Y.; Yao, L.; Zhang, B.; Zhang, S.; Guo, J. Nanoparticlemediated delivery of neurotoxin-II to the brain with intranasal administration: an effective strategy to improve antinociceptive activity of neurotoxin. Drug Dev. Ind. Pharm., 2012, 38(1), 123-8.
130. Liu, Q.; Shen, Y.; Chen, J.; Gao, X.; Feng, C.; Wang, L.; Zhang, Q.; Jiang, X. Nose-to-brain transport pathways of wheat germ agglutinin conjugated PEG-PLA nanoparticles. Pharm. Res., 2012, 29(2), 546-58.
131. Liu, Z.; Jiang, M.; Kang, T.; Miao, D.; Gu, G.; Song, Q.; Yao, L.; Hu, Q.; Tu, Y.; Pang, Z.; Chen, H.; Jiang, X.; Gao, X.; Chen, J. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials, 2013, 34(15), 3870-81.
132. Mistry, A.; Glud, S. Z.; Kjems, J.; Randel, J.; Howard, K. A.; Stolnik, S.; Illum, L. Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. J. Drug Target., 2009, 17(7), 543-52.
133. Sturm, R. Theoretical models of carcinogenic particle deposition and clearance in children's lungs. J. Thorac. Dis., 2012, 4(4), 368-76.
134. Slomkowski, S.; Gosecki, M. Progress in nanoparticulate systems for peptide, proteins and nucleic acid drug delivery. Curr. Pharm. Biotechnol., 2011, 12(11), 1823-39.
135. Heyder, J. Particle transport onto human airway surfaces. Eur. J. Respir. Dis. Suppl., 1982, 119, 29-50.
136. Depreter, F.; Pilcer, G.; Amighi, K. Inhaled proteins: challenges and perspectives. Int. J. Pharm., 2013, 447(1-2), 251-80.
137. Pirooznia, N.; Hasannia, S.; Lotfi, A. S.; Ghanei, M. Encapsulation of alpha-1 antitrypsin in PLGA nanoparticles: in vitro characterization as an effective aerosol formulation in pulmonary diseases. J. Nanobiotechnol., 2012, 10, 20.
138. Al-Qadi, S.; Grenha, A.; Carrión-Recio, D.; Seijo, B.; Remuñán-López, C. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. J. Control. Release, 2012, 157(3), 383-90.
139. Zhao, Y. Z.; Li, X.; Lu, C. T.; Xu, Y. Y.; Lv, H. F.; Dai, D. D.; Zhang, L.; Sun, C. Z.; Yang, W.; Li, X. K.; Zhao, Y. P.; Fu, H. X.; Cai, L.; Lin, M.; Chen, L. J.; Zhang, M. Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy. Acta Diabetol., 2012, 49(4), 315-25.
140. Wanakule, P.; Liu, G. W.; Fleury, A. T.; Roy, K. Nano-inside-micro: Disease-responsive microgels with encapsulated nanoparticles for intracellular drug delivery to the deep lung. J. Control. Release, 2012, 162(2), 429-37.
141. Yang, M.; Yamamoto, H.; Kurashima, H.; Takeuchi, H.; Yokoyama, T.; Tsujimoto, H.; Kawashima, Y. Design and evaluation of poly (DL-lactic-co-glycolic acid) nanocomposite particles containing salmon calcitonin for inhalation. Eur. J. Pharm. Sci., 2012, 46(5), 374-80.
142. Yang, M.; Yamamoto, H.; Kurashima, H.; Takeuchi, H.; Yokoyama, T.; Tsujimoto, H.; Kawashima, Y. Design and evaluation of inhalable chitosan-modified poly (DL-lactic-co-glycolic acid) nanocomposite particles. Eur. J. Pharm. Sci., 2012, 47(1), 235-43.
143. Tiana, X.; Lib, H.; Zhanga, D.; Shena, J.; Jiaa, L.; Zhenga, D.; Liua, G.; Haoa, L.; Shenc, Y.; Zhangd, Q. Parenteral nanosuspension of a novel synthesized antitumor candidate: Investigation of tissue biodistributions and plasma pharmacokinetics. Colloids Surf. A Physicochem. Eng. Asp., 2013, 436(0), 868-872.
144. Sun, B.; Yeo, Y. Nanocrystals for the parenteral delivery of poorly water-soluble drugs. Curr. Opin. Solid State Mater. Sci., 2012, 16(6), 295-301.
145. Sonavane, G.; Tomoda, K.; Makino, K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf. B Bio interfaces, 2008, 66(2), 274-80.
146. Li, S. D.; Huang, L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim. Biophys. Acta, 2009, 1788(10), 2259-66.
147. Li, S. D.; Huang, L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J. Control. Release; 2010, 145(3), 178-81.
148. Dufort, S.; Sancey, L.; Coll, J. L. Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution. Adv. Drug Deliv. Rev., 2012, 64(2), 179-89.
149. Ishihara, T.; Maeda, T.; Sakamoto, H.; Takasaki, N.; Shigyo, M.; Ishida, T.; Kiwada, H.; Mizushima, Y.; Mizushima, T. Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers. Biomacromolecules, 2010, 11(10), 2700-6.
150. Wong, J.; Brugger, A.; Khare, A.; Chaubal, M.; Papadopoulos, P.; Rabinow, B.; Kipp, J.; Ning, J. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv. Drug Deliv. Rev., 2008, 60(8), 939-54.
151. Hu, K.; Shi, Y.; Jiang, W.; Han, J.; Huang, S.; Jiang, X. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease. Int. J. Pharm., 2011, 415(1-2), 273-83.
152. Huile, G.; Shuaiqi, P.; Zhi, Y.; Shijie, C; Chen, C; Xinguo, J.; Shun, S.; Zhiqing, P.; Yu, H. A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Biomaterials, 2011, 32(33), 8669-75.
153. Yemisci, M.; Gürsoy-Özdemir, Y.; Caban, S.; Bodur, E.; Capan, Y.; Dalkara, T. Transport of a caspase inhibitor across the bloodbrain barrier by chitosan nanoparticles. Methods Enzymol., 2012, 508, 253-69.
154. Caban, S.; Capan, Y.; Couvreur, P.; Dalkara, T. Preparation and characterization of biocompatible chitosan nanoparticles for targeted brain delivery of peptides. Methods Mol. Biol., 2012, 846, 321-32.
155. Bao, H.; Jin, X.; Li, L.; Lv, F.; Liu, T. OX26 modified hyperbranched polyglycerol-conjugated poly (lactic-co-glycolic acid) nanoparticles: synthesis, characterization and evaluation of its brain delivery ability. J. Mater. Sci. Mater. Med., 2012, 23(8), 1891-901.
156. Xia, H.; Gao, X.; Gu, G.; Liu, Z.; Hu, Q.; Tu, Y.; Song, Q.; Yao, L.; Pang, Z.; Jiang, X.; Chen, J.; Chen, H. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int. J. Pharm., 2012, 436(1-2), 840-50.
157. Kim, J. Y.; Choi, W. I.; Kim, Y. H.; Tae, G. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronicbased nano-carrier. Biomaterials, 2013, 34(4), 1170-8.
158. Liu, Z.; Gao, X.; Kang, T.; Jiang, M.; Miao, D.; Gu, G.; Hu, Q.; Song, Q.; Yao, L.; Tu, Y.; Chen, H.; Jiang, X.; Chen, J. B6 peptidemodified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide. Bioconjug. Chem., 2013, 24(6), 997-1007.
159. Kolhar, P.; Anselmo, A. C.; Gupta, V.; Pant, K.; Prabhakarpandian, B.; Ruoslahti, E.; Mitragotri, S. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc. Natl. Acad. Sci. USA, 2013, 110(26), 10753-8.
160. Georgieva, J. V.; Kalicharan, D.; Couraud, P. O.; Romero, I. A.; Weksler, B.; Hoekstra, D.; Zuhorn, I. S. Surface characteristics of nanoparticles determine their intracellular fate in and processing by human blood-brain barrier endothelial cells in vitro. Mol. Ther., 2011, 19(2), 318-25.
161. Herwadkar, A.; Banga, A. K. Transdermal Delivery of Peptides and Proteins. In: Peptide and Protein Delivery; Elsevier Inc. 2011, p. 380.
162. Desai, P.; Patlolla, R. R.; Singh, M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol. Membr. Biol., 2010, 27(7), 247-59.
163. Rastogi, R.; Anand, S.; Koul, V. Electroporation of polymeric nanoparticles: an alternative technique for transdermal delivery of insulin. Drug Dev. Ind. Pharm., 2010, 36(11), 1303-11.
164. Vyas, S. P.; Paliwal, R.; Paliwal, S. R. Ocular Delivery of Peptides and Proteins, In: Peptide and Protein Delivery; C. V. D. Walle, Ed.; Elsevier Inc. 2011, p. 87-103.
165. Xuan, B.; McClellan, D. A.; Moore, R.; Chiou, G. C. Alternative delivery of insulin via eye drops. Diabetes Technol. Ther., 2005, 7(5), 695-8.
166. Ahsan, F.; Arnold, J.; Meezan, E.; Pillion, DJ. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm. Res., 2001, 18(12), 1742-6.
167. Chiou, G. C.; Shen, Z. F.; Zheng, Y. Q.; Li, B. H. Enhancement of systemic delivery of met-enkephalin and leu-enkephalin eyedrops with permeation enhancers. Methods Find. Exp. Clin. Pharmacol., 1992, 14(5), 361-6.
168. Vadlapudi, A. D.; Patel, A.; Cholkar, K.; Mitra, A. K. Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis. Recent Pat. Biomed. Eng., 2012, 5(1), 83-101
169. Lee, V. H.; Carson, L. W.; Kashi, S. D.; Stratford, R. Jr. Metabolic and permeation barriers to the ocular absorption of topically applied enkephalins in albino rabbits. J. Ocul. Pharmacol., 1986, 2(4), 345-52.
170. Musumeci, T.; Bucolo, C; Carbone, C; Pignatello, R.; Drago, F.; Puglisi, G. Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. Int. J. Pharm., 2013, 440(2), 135-40.
171. Aksungur, P.; Demirbilek, M.; Denkbaş, E. B.; Vandervoort, J.; Ludwig, A.; Unlü, N. Development and characterization of Cyclosporin A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies. J. Control. Release, 2011, 151(3), 286-94.
172. Yenice, I.; Mocan, M. C.; Palaska, E.; Bochot, A.; Bilensoy, E.; Vural, I.; Irkeç, M.; Hincal, A. A. Hyaluronic acid coated polyepsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. Exp. Eye Res., 2008, 87(3), 162-7.
173. Kim, H.; Csaky, K. G. Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats. J. Control. Release, 2010, 142(2), 286-93.